IMM 3.45% 30.0¢ immutep limited

chart and comments

  1. 4,906 Posts.
    lightbulb Created with Sketch. 343
    Staying on topic the chart below shows the strong support at 10 cents penetrated. Worst case scenario is the stock tracks down to the bottom trendline in time, currently 4 to 6 cents. Now that support has been penetrated at 10 cents all the buyers who bought in above this level are in the red so any attempt to push the stock price up will be met with strong resistance from some holders wanting to recoup their loses. This resistance will become stronger over time the longer the stock trades below it because more holders will lose patience and join the queue. Best case scenario is the stock makes a move to the top channel currently around 15 cents, but this is unlikely at present considering a CR will be required at some point in the near future to maintain a healthy bank balance. New trials will add some interest to the stock but as trials take many years to provide an outcome and are a drain on finances this should have little impact on the stock price. Phase2b results are due in the 4th quarter which will be another turning point for the stock. A very positive result will give the stock a boost and confidence should return ( possible interest from Pharma) A negative or ordinary result will squash any prior rally see the stock make new lows and the focus will then shift to the new trials and the process starts again. Hope that helps as sometimes the hype on stock threads can cloud the picture. The above is on topic, discussing the business of Prima Biomed and all in my opinion.

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
30.0¢
Change
0.010(3.45%)
Mkt cap ! $435.7M
Open High Low Value Volume
29.0¢ 30.5¢ 28.8¢ $574.2K 1.921M

Buyers (Bids)

No. Vol. Price($)
11 461775 30.0¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 100000 1
View Market Depth
Last trade - 16.10pm 07/08/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.